Redeye comment on the Q3 business review. Remedy reported an undramatic quarter that had a dramatic impact on the stock price, currently down almost 8%. The outlook for the year is unchanged and the business progressed as planned. No information about the sales numbers from the October release of Alan Wake Remastered could be one explanation for the sudden drop in the stock price. The negative growth should be expected by investors due to the fact that Alan Wake Remastered was released in Q4.